Loading…
Tonix Pharmaceuticals Holding Corp. is projected to rise to $16.53 by 2027, a +36% move from its current price of $12.15. TNXP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.63 | $12.17 | $12.73 | +0.16% |
| May 30 | $11.43 | $12.19 | $12.99 | +0.31% |
| May 31 | $11.29 | $12.21 | $13.20 | +0.47% |
| Jun 1 | $11.17 | $12.23 | $13.39 | +0.62% |
| Jun 2 | $11.07 | $12.24 | $13.55 | +0.78% |
| Jun 3 | $10.98 | $12.26 | $13.70 | +0.94% |
| Jun 4 | $10.90 | $12.28 | $13.85 | +1.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.90 | $12.28 | $13.85 | +1.10% |
| Week 2 | $10.48 | $12.42 | $14.71 | +2.20% |
| Week 3 | $10.20 | $12.55 | $15.45 | +3.32% |
| Week 4 | $9.99 | $12.69 | $16.13 | +4.46% |
| Week 5 | $9.81 | $12.83 | $16.77 | +5.60% |
| Week 6 | $9.67 | $12.97 | $17.40 | +6.76% |
| Week 7 | $9.55 | $13.11 | $18.01 | +7.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States.
The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia, and markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Its pipeline includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder, as well as TNX-1300, TNX-1500, TNX-4800, TNX-2900, and other programs under development; the company also pursues additional candidates such as TNX-801, TNX-4200, TNX-4900, TNX-1700, TNX-1800, and TNX-1850 among others. This portfolio reflects a broad focus across CNS, immunology, autoimmune and infectious disease areas, with operations based in Berkeley Heights, New Jersey, and a history dating back to 2007.
TNXP is a biotechnology company active in the healthcare sector with a market capitalization of $203.56M and a current price of $12.77 per share. It is ranked 3835 by market capitalization among listed equities.
In the near term, shares trade around key technical levels, with the 50-day simple moving average at $13.74 and the 200-day simple moving average at $19.48. These levels help frame the stock’s recent price action and relative strength.
The technical setup shows bearish sentiment, with RSI(14) at 40. The stock sits above the $12.40 support and below the $15.74 resistance, within a 30-day trading range of $9.35 to $17.44. Volatility remains elevated, reflecting wider price swings.
A major floor 19.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 29.5% above — a clean break opens room to run.
A major ceiling 56.5% above — clearing it would confirm fresh momentum.
Key TNXP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TNXP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.24 | Sell | $12.98 | Sell |
| MA 10 | $13.78 | Sell | $13.39 | Sell |
| MA 20 | $13.65 | Sell | $13.56 | Sell |
| MA 50 | $13.70 | Sell | $13.86 | Sell |
| MA 100 | $14.65 | Sell | $15.20 | Sell |
| MA 200 | $19.14 | Sell | $44.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.33 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -154.49 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.18 | Sell |
| ROC (12) | -13.77 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.08 | Buy |
| Awesome (5,34) | -0.26 | Sell |
| Ultimate (7,14,28) | 25.69 | Buy |
| Momentum (10) | -1.13 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 12.39 | Sell |
| ADX (14) | 9.56 | Neutral |
| ATR (14) | 0.64 | Info |
The 30-day picture is Bearish, with RSI(14) at 40 and price action generally trending below the longer‑term moving average context. The stock’s 50‑day SMA of $13.74 sits just above the current price, while the 200‑day SMA of $19.48 remains well above, signaling potential continued pressure to the downside.
Trading activity shows a 30-day range from $9.35 to $17.44, with a support level at $12.40 and a resistance at $15.74. These levels describe a domain where near-term buyers and sellers may clash, shaping follow-through moves in the weeks ahead.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.03 | $12.15 | $20.34 | 0% | Neutral | |
| $12.27 | $16.53 | $23.99 | +36% | Bullish | |
| $12.65 | $17.88 | $27.40 | +47% | Bullish | |
| $11.31 | $16.67 | $26.64 | +37% | Bullish | |
| $10.02 | $15.33 | $25.37 | +26% | Bullish | |
| $9.75 | $15.45 | $26.36 | +27% | Bullish | |
| $9.16 | $15.00 | $26.30 | +23% | Bullish | |
| $11.74 | $19.85 | $35.66 | +63% | Bullish | |
| $13.05 | $22.74 | $41.76 | +87% | Bullish | |
| $11.45 | $20.56 | $38.55 | +69% | Bullish | |
| $12.74 | $26.32 | $53.76 | +117% | Bullish | |
| $20.40 | $45.33 | $104.26 | +273% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.03 | $12.15 | $14.47 | +0.00% |
| June 2026 | $11.19 | $13.34 | $16.41 | +9.76% |
| July 2026 | $11.59 | $14.00 | $17.61 | +5.01% |
| August 2026 | $11.43 | $13.97 | $17.86 | -0.23% |
| September 2026 | $11.95 | $14.74 | $19.09 | +5.47% |
| October 2026 | $12.66 | $15.75 | $20.65 | +6.85% |
| November 2026 | $12.39 | $15.53 | $20.58 | -1.35% |
| December 2026 | $12.03 | $15.20 | $20.34 | -2.18% |
Click any year to see its month-by-month TNXP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TNXP is projected to trade between $12.03 and $20.34, averaging $12.15 — a potential gain of 0% from today's $12.15. A consolidation phase looks the most probable path here.
Tonix Pharmaceuticals Holding Corp.'s 2027 outlook centres on $16.53, within a $12.27 to $23.99 range. That is up +36% on the projected 2026 average. That marks a +36% change versus current levels. Momentum favours further upside here.
By 2028, TNXP could reach as high as $27.40, with a base case around $17.88 and support toward $12.65 — roughly +47% from $12.15. Buyers look set to stay in control over this stretch.
Expect TNXP to range from $11.31 to $26.64 through 2029. The $16.67 average target implies a +37% move from current prices. That is -7% versus the projected 2028 average. Momentum favours further upside here.
The TNXP price prediction for 2030 points to an average of $15.33 (low $10.02, high $25.37) — a potential gain of +26% on today's $12.15. Buyers look set to stay in control over this stretch.
In 2031, TNXP is projected to trade between $9.75 and $26.36, averaging $15.45 — a potential gain of +27% from today's $12.15. That is up +1% on the projected 2030 average. Momentum favours further upside here.
Tonix Pharmaceuticals Holding Corp.'s 2032 outlook centres on $15.00, within a $9.16 to $26.30 range. That is -3% versus the projected 2031 average. That marks a +23% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TNXP could reach as high as $35.66, with a base case around $19.85 and support toward $11.74 — roughly +63% from $12.15. Momentum favours further upside here.
Expect TNXP to range from $13.05 to $41.76 through 2034. The $22.74 average target implies a +87% move from current prices. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TNXP price prediction for 2035 points to an average of $20.56 (low $11.45, high $38.55) — a potential gain of +69% on today's $12.15. Momentum favours further upside here.
In 2040, TNXP is projected to trade between $12.74 and $53.76, averaging $26.32 — a potential gain of +117% from today's $12.15. That is up +28% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Tonix Pharmaceuticals Holding Corp.'s 2050 outlook centres on $45.33, within a $20.40 to $104.26 range. That is up +72% on the projected 2040 average. That marks a +273% change versus current levels. Momentum favours further upside here.
Investing $1,000 in TNXP today (≈ 82.304527 TNXP) could be worth
$3,730.73
+$2,730.73 (+273%) by 2050 · US Dollar
Based on the average projected TNXP price of $45.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TNXPwould be worth at today's price.
$1,000 invested in TNXP on May 27, 2025 (≈ 27.034332 TNXP) would be worth
$328.47
-$671.53 (-67.2%) today · 0.33× · US Dollar
Based on a TNXP entry price of $36.99 vs. today's $12.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.5 | $837.93 | -16.2% |
| 1 month ago | $12.84 | $946.26 | -5.4% |
| 3 months ago | $14.43 | $842 | -15.8% |
| 6 months ago | $15.97 | $760.8 | -23.9% |
| 1 year ago | $36.99 | $328.47 | -67.2% |
| All time (5.0y) ago | $793,600 | $0.02 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TNXP forecast.
Our base-case forecast reaches $24.00 around 2040.
Implied market cap at $24.00: $382.58M
The multi-year forecast paints a bullish arc beyond 2026, with gradual appreciation in the average price and sizeable upside potential in later years.
In 2027 the average price is projected to be $17.65 with a bullish sentiment, and in 2028 the average moves to $18.82. The 2033–2035 stretch shows stronger upside, with 2033 average $21.64 and max $39.48 (ROI 69.5%), 2034 average $24.38 and max $45.51 (ROI 90.9%), and 2035 average $22.14 with max $42.21 (ROI 73.3%).
Longer-dated forecasts show continued strength, with 2040 average $28.76 and max $59.84 (ROI 125.2%), and 2050 average $49.23 and max $113.22 (ROI 285.5%). The 2026 forecast sits at average $12.77 with sentiment Neutral, while the long‑term outlook remains Bullish as the yearly averages rise and upside potential expands. The forecast also notes an annualized volatility of 90% as a measure of risk and variability over the period.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $16.19 with a range from $10.42 to $27.14 and an ROI of 26.7%. The sentiment is Bullish.
Forecasts indicate a bullish trajectory beyond 2026, with 2027 avg $17.65, rising through 2050 to an avg of $49.23 and max of $113.22, and ROIs up to 285.5% by 2050. The 2026 entry is Neutral, so outcomes depend on future conditions and timing.
Yes. The maximum forecast by 2050 is $113.22, which exceeds $100.
$9.35 to $17.44.
Tonix Pharmaceuticals Holding Corp. Community Discussion
0Share your Tonix Pharmaceuticals Holding Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.